Pyoderma gangrenosum - Pioderma Gangrenós
Pioderma Gangrenós (Pyoderma gangrenosum) és una malaltia inflamatòria rara de la pell en la qual les pústules o nòduls dolorosos es converteixen en úlceres que creixen progressivament. Pioderma gangrenós (pyoderma gangrenosum) no és infecciosa. Els tractaments poden incloure corticoides, ciclosporina o diversos anticossos monoclonals. Tot i que pot afectar persones de qualsevol edat, és més freqüent entre els 40 i 50 anys.
☆ AI Dermatology — Free Service
En els resultats de la Stiftung Warentest d'Alemanya de 2022, la satisfacció dels consumidors amb ModelDerm va ser només lleugerament inferior a la de les consultes de telemedicina de pagament.
En els resultats de la Stiftung Warentest d'Alemanya de 2022, la satisfacció dels consumidors amb ModelDerm va ser només lleugerament inferior a la de les consultes de telemedicina de pagament.
A la cama d'una persona amb colitis ulcerosa.
relevance score : -100.0%
ReferencesPyoderma gangrenosum és una malaltia rara de la pell que causa úlceres doloroses amb vores vermelles o violetes. Està classificada com una malaltia inflamatòria i forma part d'un grup anomenat dermatosi neutròfila. La causa del pyoderma gangrenosum és complexa i implica problemes de la immunitat innata i adaptativa en persones genèticament predisposades. Recentment, els investigadors s'han centrat en el fol·licle pilós com a possible punt d'inici de la malaltia.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum és una malaltia rara de la pell que causa úlceres extremadament doloroses. Tot i que no entenem completament la seva causa, sabem que implica una major activitat de determinades cèl·lules immunitàries. Tractar la malaltia encara no és fàcil. Disposem de diversos fàrmacs que suprimeixen el sistema immunitari o modifiquen la seva activitat. A més, ens centrem en el tractament de les ferides i en la gestió del dolor. Els corticosteroides i la ciclosporina solen ser la primera opció per al tractament, però darrerament s'han realitzat més investigacions sobre l'ús de teràpies biològiques, com els inhibidors del TNF-α. Aquests productes biològics són cada cop més preferits, especialment en pacients amb altres afeccions inflamatòries, i s'utilitzen més aviat en el curs de la malaltia.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
